These subgroups exhibit differential responses to ICIs, with the KP subtype demonstrating higher levels of tumor-infiltrating lymphocytes (TILs) and increased PD-L1 expression, leading to more favorable outcomes with immunotherapy. The gene discussed is CD274; the disease is neoplasm.